Format

Send to

Choose Destination
Assay Drug Dev Technol. 2017 Apr;15(3):113-119. doi: 10.1089/adt.2016.772. Epub 2017 Apr 5.

Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.

Author information

1
1 Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center , Nashville, Tennessee.
2
2 Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine , Nashville, Tennessee.
3
3 Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee.
4
4 Department of Biomedical Informatics, Vanderbilt University School of Medicine , Nashville, Tennessee.
5
5 Center for Technology Transfer and Commercialization, Vanderbilt University , Nashville, Tennessee.
6
6 Office of Research, Vanderbilt University Medical Center , Nashville, Tennessee.
7
7 Department of Pathology, Microbiology, and Immunology, Division of Molecular Pathogenesis, Vanderbilt University School of Medicine , Nashville, Tennessee.
8
8 Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center , Nashville, Tennessee.
9
9 Vanderbilt Kennedy University Center for Excellence in Development Disabilities, Nashville, Tennessee.
10
10 Department of Chemistry, Vanderbilt University , Nashville, Tennessee.
11
11 Department of Biochemistry, Vanderbilt University Medical School , Nashville Tennessee.
12
12 Department of Medicinal Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center , Nashville, Tennessee.
13
13 Nashville Biosciences, Nashville, Tennessee.
14
14 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University School of Medicine , Nashville, Tennessee.
15
15 Department of Cell and Developmental Biology, Vanderbilt University School of Medicine , Nashville, Tennessee.

Abstract

The potential impact of using human genetic data linked to longitudinal electronic medical records on drug development is extraordinary; however, the practical application of these data necessitates some organizational innovations. Vanderbilt has created resources such as an easily queried database of >2.6 million de-identified electronic health records linked to BioVU, which is a DNA biobank with more than 230,000 unique samples. To ensure these data are used to maximally benefit and accelerate both de novo drug discovery and drug repurposing efforts, we created the Accelerating Drug Development and Repurposing Incubator, a multidisciplinary think tank of experts in various therapeutic areas within both basic and clinical science as well as experts in legal, business, and other operational domains. The Incubator supports a diverse pipeline of drug indication finding projects, leveraging the natural experiment of human genetics.

KEYWORDS:

BioVU; PheWAS; genetics; repurposing; translational research

PMID:
28379727
PMCID:
PMC5399743
DOI:
10.1089/adt.2016.772
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center